Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

U.S. News

Gilead and J&J Expand HIV Cocktail Partnership

November 16, 2011

Gilead Sciences Inc. and Johnson & Johnson's Tibotec division announced Tuesday they will work together to develop a new HIV pill that contains Tibotec's Prezista and Gilead's Emtriva. The tablet also will include Gilead's drug candidates cobicistat and GS 7340, which are not yet approved. Under the arrangement, Gilead will be responsible for manufacturing the drug, handling the regulatory process and selling the medication. Tibotec will retain co-marketing rights in some countries. The companies also partnered to develop Complera, which combines Gilead's Truvada with J&J's Edurant; it was approved in August.

Back to other news for November 2011

Adapted from:
Boston Globe
11.15.2011; Associated Press


  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More on HIV Medications
HIV Drugs in Development

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement